ResearchPod Summary
Major depressive disorder (MDD) is often treated with antidepressants that require weeks to show clinical benefits, leaving patients in a state of uncertainty during initial trial periods. This study sought to identify neurophysiological markers—specifically regarding the dorsolateral prefrontal cortex (DLPFC)—that could predict treatment success early in the course of medication administration. The researchers investigated whether task-based EEG/ERP activity and functional connectivity (FC) could serve as state-dependent biomarkers for therapeutic response.
The researchers conducted a prospective longitudinal study with 115 patients diagnosed with MDD and 43 healthy controls. All patients were treated with the antidepressant venlafaxine for 12 weeks. Using a visual oddball paradigm, the team recorded EEG data at baseline and one week after treatment initiation. They performed source localization analysis to quantify current density in the DLPFC and utilized the phase lag index (PLI) to measure functional connectivity between the DLPFC and other key nodes of the default mode network (PCC) and salience network (Insula).
Patients with MDD demonstrated significantly reduced right DLPFC current density compared to healthy controls at baseline. Within one week of treatment, patients who achieved eventual remission (at week 12) showed a pronounced increase in right DLPFC current density across several time windows (N1, P2, N2, and P3). Furthermore, a reduction in beta-band functional connectivity between the left DLPFC and the posterior cingulate cortex (PCC) during this early one-week window emerged as a statistically significant predictor of treatment remission. These results suggest that early neurophysiological shifts—specifically the normalization of DLPFC activity and the decoupling of the DLPFC from default mode regions—are indicative of a successful path toward recovery.
These findings suggest that EEG-based biomarkers could provide an accessible, low-cost, and rapid method to evaluate whether a patient is likely to respond to a prescribed antidepressant. By identifying these early signatures, clinicians might one day be able to identify ineffective treatment trials within just one week, allowing for more personalized and timely intervention strategies that could reduce the prolonged suffering associated with ineffective pharmacological trials.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.